To understand the competitive nature of the induced pluripotent stem cell (iPSC) research products market, it is important to consider the degree of competition that has entered the market since the discovery of the cell type in 2006.
Currently, there are more than 40 companies offering iPSC research products. The change in the number of companies offering iPSC research products increased substantially from 2013 to 2014 (29%), because there were 31 companies offering iPSC research products in 2013, and that number increased to 40 by 2014. In 2015, Pluriomics was a notable newcomer to the iPSC products scene.
Three companies specializing in iPSC research products are ReproCELL, Axol Bioscience, and Cellular Dynamics International (CDI), which was acquired by FUJIFILM Holdings Corporation for $307 million in March 2015.
ReproCELL was established in 2009 as a venture company originating from the University of Tokyo and Kyoto University and was the first company to launch a commercial iPSC product. It released a human iPSC-derived cardiomyocyte product, called “ReproCario.” [Read more…]